TY - JOUR T1 - High Levels of Wilms' Tumor 1 (WT1) Expression Were Associated with Aggressive Clinical Features in Ovarian Cancer JF - Anticancer Research JO - Anticancer Res SP - 2331 LP - 2340 VL - 34 IS - 5 AU - ZHIYANG LIU AU - KEIKO YAMANOUCHI AU - TSUYOSHI OHTAO AU - SOHEI MATSUMURA AU - MANABU SEINO AU - VIJI SHRIDHAR AU - TOSHIFUMI TAKAHASHI AU - KAZUHIRO TAKAHASHI AU - HIROHISA KURACHI Y1 - 2014/05/01 UR - http://ar.iiarjournals.org/content/34/5/2331.abstract N2 - Aim: The aim of the present study was to evaluate the correlation between WT1 expression levels and clinical features, to investigate the prognostic value of WT1 expression and to use lentiviral constructs to examine whether overexpression of WT1 affects cell proliferation and invasion in ovarian cancer patients. Materials and Methods: Real-time quantitative PCR (qPCR) methods were employed to analyze WT1 expression levels in clinical samples from 63 patients with ovarian cancer. The correlation between the copy number of WT1 mRNA and clinical variables was analyzed. Results: The median copy number of WT1 mRNA was 53.94 (range=2.135-32,257) in all subjects and WT1 expression levels were found significantly increased in patients with a higher stage cancer (p<0.05), lymphnode (p<0.001) and omentum metastasis (p<0.001), as well as ascites production (p<0.05), compared to patients lacking these clinical variables. No significant difference in WT1 expression levels were observed between patients with and without recurrence. The median disease-free survival time in patients with low WT1 expression levels was significantly longer (p=0.038) than that in patients with high WT1 expression. However, overall survival curves showed no statistically significant (p=0.457) differences between patients with high- and low-WT1 expression levels. An in vitro study revealed that WT1 over-expression enhanced cell proliferation and invasion in ovarian cancer cells transduced with lentiviral constructs. Conclusion: Using qPCR, we found that high levels of WT1 expression correlated with aggressive clinical features in ovarian cancer. High WT1 expression may impact on median disease-free survival in ovarian cancer. ER -